| Search by tag or site | Login to my blog ? Start my own blog |
![]() |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Abc And Cbs Give No Credit To Novartis
Posted on 05/14/2007 22:09:07 | Link | Post Comment
by Julia A. Seymour
Business & Media Institute
Evening broadcasts praise 'promising' drug for osteoporosis without naming the manufacturer.
Both ABC and CBS evening news programs praised a new drug that could save lives threatened by osteoporosis. But they didn’t say what company spent years and millions of dollars developing it.
ABC “World News” anchor Charles Gibson called it “promising news.”
“CBS Evening News” anchor Katie Couric agreed, saying the new drug “may be just what the doctor ordered” for the 10 million Americans living with the disease.
The wonder drug hailed by both “Evening News” and “World News with Charles Gibson” on May 2 is zoledronic acid.
It is sold under the brand names Reclast and Zometa. But neither CBS nor ABC mentioned the maker of the new treatment: Novartis Pharmaceuticals (NVS).
Novartis should have been given credit for the innovative new drug, since it likely cost them millions in research and development costs. The Pharmaceutical Research and Manufacturers of America estimates the cost of an approved new drug to be more than $800 million.
Zoledronic acid differs from other osteoporosis medications because it can be injected through an IV in about 15 minutes, and only has to be given once a year.
Both broadcasts cited a study of postmenopausal women that resulted in a 70-percent decline in spine fractures and a 41-percent decline in hip fractures.
“Experts say reducing fractures can save lives,” said “Evening News” medical correspondent Dr. Jon LaPook.
The study did find an irregular heartbeat to be a potential side effect, which both programs reported.
Ignoring pharmaceutical companies and development costs is common in media coverage of the industry. In fact, between Jan. 1 and Sept. 20, 2006, only 22 percent of network stories named the company that developed the drug in question and only 2 percent of stories included cost, according to a Business & Media Institute study.
Source: BusinessAndMedia.org
RELATED READING:
- "60 Minutes" Takes 13 Minutes to Attack Drug Companies
- Cancer Drug, but not Drug Company, Praised by Networks
____________________
Business & Media Institute
Evening broadcasts praise 'promising' drug for osteoporosis without naming the manufacturer.
Both ABC and CBS evening news programs praised a new drug that could save lives threatened by osteoporosis. But they didn’t say what company spent years and millions of dollars developing it.
ABC “World News” anchor Charles Gibson called it “promising news.”
“CBS Evening News” anchor Katie Couric agreed, saying the new drug “may be just what the doctor ordered” for the 10 million Americans living with the disease.
The wonder drug hailed by both “Evening News” and “World News with Charles Gibson” on May 2 is zoledronic acid.
It is sold under the brand names Reclast and Zometa. But neither CBS nor ABC mentioned the maker of the new treatment: Novartis Pharmaceuticals (NVS).
Novartis should have been given credit for the innovative new drug, since it likely cost them millions in research and development costs. The Pharmaceutical Research and Manufacturers of America estimates the cost of an approved new drug to be more than $800 million.
Zoledronic acid differs from other osteoporosis medications because it can be injected through an IV in about 15 minutes, and only has to be given once a year.
Both broadcasts cited a study of postmenopausal women that resulted in a 70-percent decline in spine fractures and a 41-percent decline in hip fractures.
“Experts say reducing fractures can save lives,” said “Evening News” medical correspondent Dr. Jon LaPook.
The study did find an irregular heartbeat to be a potential side effect, which both programs reported.
Ignoring pharmaceutical companies and development costs is common in media coverage of the industry. In fact, between Jan. 1 and Sept. 20, 2006, only 22 percent of network stories named the company that developed the drug in question and only 2 percent of stories included cost, according to a Business & Media Institute study.
Source: BusinessAndMedia.org
RELATED READING:
- "60 Minutes" Takes 13 Minutes to Attack Drug Companies
- Cancer Drug, but not Drug Company, Praised by Networks
____________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
![]()
- Trader X
- Real Estate Marketing Blog
- Morpheus Trading
- Alpha Trends
- Millionaire Now! by Larry Nusbaum
- Random Roger's Big Picture
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
When I first started Day Trading I traded anything that [read more]
Morpheus Trading - Thu Oct 02, 2008 08:58AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]












<< My Home | TheMoneyBlogs Home